Disease-modifying drugs for multiple sclerosis: current and future aspects.

Disease-modifying drugs for multiple sclerosis: current and future aspects.

Item
http://www.wikidata.org/entity/Q36613906
Therapeutic efficacy of monthly subcutaneous injection of daclizumab in relapsing multiple sclerosisSubcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.Drug adherence and multidisciplinary care in patients with multiple sclerosis: protocol of a prospective, web-based, patient-centred, nation-wide, Dutch cohort study in glatiramer acetate treated patients (CAIR study)Dimethyl fumarate and monoethyl fumarate exhibit differential effects on KEAP1, NRF2 activation, and glutathione depletion in vitro.Persistence and adherence in multiple sclerosis patients starting glatiramer acetate treatment: assessment of relationship with care received from multiple disciplinesGlatiramer acetate treatment persistence - but not adherence - in multiple sclerosis patients is predicted by health-related quality of life and self-efficacy: a prospective web-based patient-centred study (CAIR study).Altered Toll-like receptor 2-mediated endotoxin tolerance is related to diminished interferon beta production.Evidence of activation of the Nrf2 pathway in multiple sclerosis patients treated with delayed-release dimethyl fumarate in the Phase 3 DEFINE and CONFIRM studies.Exploratory analysis of predictors of patient adherence to subcutaneous interferon beta-1a in multiple sclerosis: TRACER study.Long-term adherence of patients with relapsing-remitting multiple sclerosis to subcutaneous self-injections of interferon β-1a using an electronic device: the RIVER study.Multiple sclerosis: reduced proportion of circulating plasmacytoid dendritic cells expressing BDCA-2 and BDCA-4 and reduced production of IL-6 and IL-10 in response to herpes simplex virus type 1.Allelic combinations of immune-response genes associated with glatiramer acetate treatment response in Russian multiple sclerosis patients.
P2860

Disease-modifying drugs for multiple sclerosis: current and future aspects.

Item
http://www.wikidata.org/entity/Q36613906
description
2006 nî lūn-bûn
@nan
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
2006年论文
@zh
2006年论文
@zh-cn
name
Disease-modifying drugs for multiple sclerosis: current and future aspects.
@ast
Disease-modifying drugs for multiple sclerosis: current and future aspects.
@en
type
label
Disease-modifying drugs for multiple sclerosis: current and future aspects.
@ast
Disease-modifying drugs for multiple sclerosis: current and future aspects.
@en
prefLabel
Disease-modifying drugs for multiple sclerosis: current and future aspects.
@ast
Disease-modifying drugs for multiple sclerosis: current and future aspects.
@en
P1433
P1476
P2093
P2860
P304
P31
P356
P407
P478
P577
P698
P921
P356
P1433
P1476
Disease-modifying drugs for multiple sclerosis: current and future aspects.
@en
P2093
P2860
P304
P31
P356
P407
P478
P577
P698
P921